Nachrichten zur AstraZeneca PLC Aktie

nirsevimab recommended for infant RSV protection

9 June 2023 Nirsevimab unanimously recommended by FDA Advisory Committee for the prevention of RSV lower respiratory tract disease in infants If approved,…

AstraZeneca agreement with Quell Therapeutics

09 June 2023 AstraZeneca announces agreement with Quell Therapeutics to develop, manufacture and commercialise engineered T-regulatory cell therapies for autoimmune diseases Collaboration focused on…

AstraZeneca, Sanofi win FDA advisory committee backing for RSV therapy nirsevimab

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Infant RSV Drug From Sanofi, AstraZeneca Wins Backing of Key ...

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

FDA advisers vote in favor of AstraZeneca, Sanofi antibody for infant RSV protection

Advisers to the U.S. Food and Drug Administration voted unanimously Thursday to recommend a monoclonal antibody developed by Sanofi SNY…

FDA advisors recommend AstraZeneca antibody to protect babies from RSV

If the Food and Drug Administration approves nirsevimab, it will be the first medical intervention available in the U.S. that…

AstraZeneca: Broker upbeat after American cancer conference data ...

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

AstraZeneca and Daiichi Sankyo report progress in cancer drug trials

Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…

AstraZeneca (AZN) Anticoagulant Drug Study Meets Efficacy Goal

At the interim analysis, AstraZenecas (AZN) drug Andexxa showed superior hemostatic efficacy or in other words improved control of bleeding…

Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....…

AstraZeneca Reports Positive Results From Interim Analysis Of DESTINY-PanTumor02 Phase II Trial

LONDON (dpa-AFX) - AstraZeneca PLC (AZN.L, AZN) and Daiichi Sankyos Enhertu showed an objective response rate of 37.1% in the…

AstraZeneca Neutral

ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Astrazeneca auf "Neutral" mit einem Kursziel von 12500…

AstraZeneca Cancer Drug Enhertu Shows Clinically Meaningful, Durable Response in Trial

AstraZeneca Cancer Drug Enhertu Shows Clinically Meaningful, Durable Response in Trial...…

AstraZeneca stops Andexxa trial early, Tagrisso reduces death risk

Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…

AstraZeneca Says Andexxa Phase IV Trial Stopped Early On Achieving Efficacy Goal

LONDON (dpa-AFX) - AstraZeneca PLC (AZN.L) on Monday said the Phase 4 study of Andexxa in patients on oral FXa-inhibitor…

Lung cancer pill cuts risk of death by half, study finds

The drug, developed by AstraZeneca, if taken daily after surgery, dramatically reduces risk of death, study shows....…

AstraZeneca to Stop Intracranial Hemorrhage Drug Trial After Criteria Met

AstraZeneca to Stop Intracranial Hemorrhage Drug Trial After Criteria Met...…

AstraZeneca Announces Positive Results From Interim Analysis Of DUO-O Phase III Trial

LONDON (dpa-AFX) - AstraZeneca PLC (AZN.L, AZN) announced positive results from interim analysis of DUO-O Phase III trial showed that…

FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer

Following FDAs label-expansion approval, AstraZenecas (AZN)/Mercks (MRK) Lynparza is the first PARP inhibitor approved in combination with a new hormonal…

Top Research Reports for Exxon Mobil, AstraZeneca & Netflix

Todays Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), AstraZeneca PLC (AZN) and…

AstraZeneca sees positive results for Imfinzi in gastric cancers

Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…

AstraZeneca Says Imfinzi Data Shows Improved Response in Gastric Cancers

AstraZeneca Says Imfinzi Data Shows Improved Response in Gastric Cancers...…

Form 6-K ASTRAZENECA PLC For: Jun 02

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Imfinzi improved pCR in gastric and GEJ cancers

2 June 2023 Imfinzi plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial First global…

Fact Check-É falso que Fiocruz parou de produzir vacina contra Covid-19 da AstraZeneca

...Por Reuters Fact Check 1…

AstraZeneca halts bowel disease drug program

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AstraZeneca and OMP Present the Journey Toward the Power of Decision Intelligence at Gartner Supply Chain Symposium/Xpo in Barcelona

BARCELONA, SPAIN / ACCESSWIRE / June 1, 2023 / OMP, a leading provider of supply chain planning solutions, invites attendees…

Form 6-K ASTRAZENECA PLC For: Jun 01

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

AstraZeneca (AZN) Discontinues Brazikumab Development

AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program....…

AstraZeneca halts AbbVie-partnered bowel disease drug program

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AstraZeneca Announces Discontinuation Of IBD Development Programme For Brazikumab

LONDON (dpa-AFX) - AstraZeneca PLC (AZN.L, AZN) announced the discontinuation of the brazikumab inflammatory bowel disease development programme, being investigated…

TOP NEWS: AstraZeneca discontinues brazikumab; Lynparza wins approval

Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…

AstraZeneca drug combo gets US nod to treat a type of prostate cancer

...(Reuters) - AstraZeneca said on Thursday that a combination......…

AstraZeneca Discontinues Brazikumab Inflammatory Bowel Disease Development Program

AstraZeneca Discontinues Brazikumab Inflammatory Bowel Disease Development Program...…

AstraZeneca to stop brazikumab inflammatory bowel disease programme

...June 1 (Reuters) - British drugmaker AstraZeneca said on Thursday......…

AstraZeneca Says US Approved Lynparza as a Prostate Cancer Treatment

AstraZeneca Says US Approved Lynparza as a Prostate Cancer Treatment...…

BRIEF-Astrazeneca: Lynparza Approved In US For BRCam Prostate Cancer

...June 1 (Reuters) - AstraZeneca PLC: * ASTRAZENECA PLC - LYNPARZA......…

BioLight Inks Agreement With Alexion To Explore Technology For Diagnosis Of Retinal Diseases

LONDON (dpa-AFX) - BioLight Life Sciences Ltd. announced Tuesday it has signed a research collaboration agreement with Alexion Pharmaceuticals, Inc.…

BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases

TEL AVIV, Israel, May 30, 2023 /PRNewswire/ -- BioLight (TASE: BOLT) is proud to report it has signed a research…

dpa-AFX ProFeed